

Table SI. Chemotherapy completion.

Cycles	AS group (n=49)	GS group (n=52)
Overall completed cycles, n	373.5	410
Number of cycles, median (IQR)	7 (2.50-11.0)	6.5 (3.25-12.75)
Number of cycles, n (%)		
1.0	46 (93.87)	52 (100.00)
2.0	42 (85.71)	49 (94.23)
6.0	30 (61.22)	30 (57.69)
12.0	10 (20.41)	11 (21.15)
18.0	5 (10.20)	5 (9.61)
23.0	1 (2.04)	0 (0)

AS, nab-paclitaxel plus S-1; GS, gemcitabine plus S-1; IQR, interquartile range.

Table SII. Post-discontinuation anticancer therapies.

Concomitant therapies	N (%)	
	AS group (n=49)	GS group (n=52)
Second-line	29 (59.18)	34 (65.38)
Gemcitabine-based regimen	16 (32.65)	0 (0)
Nab-paclitaxel-based regimen	2 (4.08)	19 (36.54)
Irinotecan/oxaliplatin-based regimen	2 (4.08)	7 (13.46)
Radiotherapy-based regimen	4 (8.16)	4 (7.69)
Traditional Chinese medicine	3 (6.12)	2 (3.85)
Other	2 (4.08)	2 (3.85)
Third-line	8 (16.33)	7 (13.46)
Gemcitabine-based regimen	3 (6.12)	0 (0)
Nab-paclitaxel-based regimen	0 (0)	2 (3.85)
Irinotecan-based regimen	2 (4.08)	0 (0)
Nab-paclitaxel-based regimen	0 (0)	2 (3.85)
Fluorouracil-based regimen	2 (4.08)	0 (0)
Other	1 (2.04)	3 (5.77)

AS, nab-paclitaxel plus S-1; GS, gemcitabine plus S-1.